1086 related articles for article (PubMed ID: 9001980)
1. The prognostic significance of basic fibroblast growth factor in cutaneous malignant melanoma.
al-Alousi S; Barnhill R; Blessing K; Barksdale S
J Cutan Pathol; 1996 Dec; 23(6):506-10. PubMed ID: 9001980
[TBL] [Abstract][Full Text] [Related]
2. Expression of basic fibroblast growth factor in desmoplastic melanoma.
al-Alousi S; Carlson JA; Blessing K; Cook M; Karaoli T; Barnhill RL
J Cutan Pathol; 1996 Apr; 23(2):118-25. PubMed ID: 8721445
[TBL] [Abstract][Full Text] [Related]
3. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression.
Straume O; Akslen LA
Am J Pathol; 2002 Mar; 160(3):1009-19. PubMed ID: 11891198
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression.
Reed JA; McNutt NS; Albino AP
Am J Pathol; 1994 Feb; 144(2):329-36. PubMed ID: 8311116
[TBL] [Abstract][Full Text] [Related]
5. Immunologic escape and angiogenesis in human malignant melanoma.
Redondo P; Sánchez-Carpintero I; Bauzá A; Idoate M; Solano T; Mihm MC
J Am Acad Dermatol; 2003 Aug; 49(2):255-63. PubMed ID: 12894074
[TBL] [Abstract][Full Text] [Related]
6. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma.
Straume O; Jackson DG; Akslen LA
Clin Cancer Res; 2003 Jan; 9(1):250-6. PubMed ID: 12538477
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive dynamic fluorescence imaging of human melanomas reveals that targeted inhibition of bFGF or FGFR-1 in melanoma cells blocks tumor growth by apoptosis.
Valesky M; Spang AJ; Fisher GW; Farkas DL; Becker D
Mol Med; 2002 Feb; 8(2):103-12. PubMed ID: 12080186
[TBL] [Abstract][Full Text] [Related]
8. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
[TBL] [Abstract][Full Text] [Related]
9. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma.
Piras F; Murtas D; Minerba L; Ugalde J; Floris C; Maxia C; Colombari R; Perra MT; Sirigu P
Histopathology; 2007 Jun; 50(7):835-42. PubMed ID: 17543072
[TBL] [Abstract][Full Text] [Related]
10. Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma.
Corte MD; Gonzalez LO; Corte MG; Quintela I; Pidal I; Bongera M; Vizoso F
Int J Biol Markers; 2005; 20(4):242-8. PubMed ID: 16398406
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical localization of basic fibroblast growth factor in skin diseases.
Yaguchi H; Tsuboi R; Ueki R; Ogawa H
Acta Derm Venereol; 1993 Apr; 73(2):81-3. PubMed ID: 8103271
[TBL] [Abstract][Full Text] [Related]
12. [Expression of neutral endopeptidase and motility-related protein-1 in cutaneous malignant melanoma].
Wu Y; Zhang XB; Liu HJ; Zheng LD; Li JW; Lin Y
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):466-9. PubMed ID: 17845760
[TBL] [Abstract][Full Text] [Related]
13. Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma - from the population-based Swedish melanoma register.
Lyth J; Falk M; Maroti M; Eriksson H; Ingvar C
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1468-1474. PubMed ID: 28419674
[TBL] [Abstract][Full Text] [Related]
14. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma.
Giehl KA; Nägele U; Volkenandt M; Berking C
J Cutan Pathol; 2007 Jan; 34(1):7-14. PubMed ID: 17214848
[TBL] [Abstract][Full Text] [Related]
15. The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblastic growth factor.
Demirkesen C; Büyükpinarbaşili N; Ramazanoğlu R; Oğuz O; Mandel NM; Kaner G
Pathology; 2006 Apr; 38(2):132-7. PubMed ID: 16581653
[TBL] [Abstract][Full Text] [Related]
16. Expression analysis of ovostatin 2 reveals its involvement in proliferation, invasion and angiogenesis of cutaneous malignant melanoma.
Huang YX; Qi J; Wang HS; Shao XB; Zeng XS; Li AM; Xu XL; Sun JF
J Dermatol; 2013 Nov; 40(11):901-10. PubMed ID: 24112097
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of HER-2 in thick melanoma.
Eliopoulos P; Mohammed MQ; Henry K; Retsas S
Melanoma Res; 2002 Apr; 12(2):139-45. PubMed ID: 11930110
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma.
Henrique R; Azevedo R; Bento MJ; Domingues JC; Silva C; Jerónimo C
J Am Acad Dermatol; 2000 Dec; 43(6):991-1000. PubMed ID: 11100014
[TBL] [Abstract][Full Text] [Related]
19. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression.
Reed JA; McNutt NS; Bogdany JK; Albino AP
J Cutan Pathol; 1996 Dec; 23(6):495-505. PubMed ID: 9001979
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical localization of basic fibroblast growth factor in astrocytomas.
Zagzag D; Miller DC; Sato Y; Rifkin DB; Burstein DE
Cancer Res; 1990 Nov; 50(22):7393-8. PubMed ID: 2171762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
